Listen to our guest, Dr. Suneil Hosmane (Executive Vice President and Global Head of Diagnostics at GENFIT), as he speaks about the role of AI digital pathology, the latest NIS4 blood-based diagnostic test by Genfit and how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts in NASH clinical trials today that could ultimately transform the NASH clinical care pathway.
Introduction of Dr. Suneil HosmaneDr. Suneil Hosmane,Ph.D.Executive Vice President and Global Head of Diagnostics at GENFIT
Suneil Hosmane has served as Head of Global Diagnostics at GENFIT since October 2019. Prior to that Suneil served as the Executive Vice President of Strategic Development at GENFIT Corp., which he joined at the end of 2017. He has had a leadership role on multiple strategic initiatives that span across GENFIT’s therapeutic and diagnostic programs. Prior to joining GENFIT, he held positions of increasing responsibility at Becton Dickinson Diagnostics, Intercept Pharmaceuticals, and EchoSens.